Order Summary

In order to access content on the Celltelligence Library, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information Already have an account? Log in here

*
LEAVE THIS BLANK
 

By selecting this, I agree to receive emails from celltelligence.com.


You will be granted access to your Celltelligence Library to view the full article after sign up.

Different Strategies for Enhancing CAR-Ts to Treat Solid Tumors; Preclinical Results from Allogene’s ALLO-316; TCR2 Tx’s Allogeneic TRuC-T Platform; AACR 2022 Analysis 4

Here is a brief preview of this blast: AACR 2022 Analysis 4: Several key cell therapy-related topics were discussed to overcome the challenges associated with utilizing CAR-Ts for solid tumors. Additionally, preclinical results were presented from Allogene and TCR2 Tx. Below, Celltelligence provides insights and context for each presentation. The following topics are covered below:

About The Author

Mark McCully, PhD

|
Senior Content Lead
Mark McCully, PhD is the Content Lead for Celltelligence covering the dynamic and rapidly evolving cell therapy space. Mark regularly attends large and small cell therapy scientific meetings to build upon his decade of oncology R&D experience. To that end, Mark previously worked on numerous consulting projects for large cap pharma and emerging biotech to help characterize the ever-changing landscape.